Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes. METHODS/PRINCIPAL FINDINGS: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of 11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49-0.88) for cancer mortality, 0.67 (0.53-0.85) for all-cancer incidence, 0.68 (0.53-0.88) for colorectal cancer (n = 6), 0.20 (0.07-0.59) for hepatocellular cancer (n = 4), 0.67 (0.45-0.99) for lung cancer (n = 3). CONCLUSION/SIGNIFICANCE: The use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“All the procedures were in accordance with the guidelines for the Quality of Reporting of Meta-analyses [24], the meta-analysis of observational studies in epidemiology [25] and the PRISMA statement [26].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“In light of the fact that cancer is the second and diabetes the twelfth leading cause of death worldwide [59] and that the number of people with diabetes is”
Background
Cited by
Items 201–300 of 580
Metformin Effects on FOXP3+ and CD8+ T Cell Infiltrates of Head and Neck Squamous Cell Carcinoma
Amin, D. R., Richa, T., Mollaee, M., Zhan, T., Tassone, P. T., Johnson, J. M., Luginbuhl, A., Cognetti, D. M., Martinez‐Outschoorn, U., Stapp, R., et al. (2019) · The Laryngoscope · doi:10.1002/lary.28336 · Cited by 42
Targeting ageing and preventing organ degeneration with metformin
Sunjaya, A. P., & Sunjaya, A. F. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.009 · Cited by 37
Report of the JDS/JCA Joint Committee on Diabetes and Cancer
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0121-3 · Cited by 40
“In contrast, with regard to the biguanide metformin, which is used to improve insulin resistance, metformin users have been shown to be at a lower risk of cancer than non-users [123].”
BackgroundResultSelf-citationAssociation of diabetes and diabetes treatment with incidence of breast cancer
García‐Esquinas, E., Guinó, E., Castaño‐Vinyals, G., Pérez‐Gómez, B., Llorca, J., Altzibar, J. M., Peiró, R., Martín, V., Moreno-Iribas, C., Tardón, A., et al. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0756-6 · Cited by 41
“Results from most meta-analyses have suggested a nonsignificant decreased risk of breast cancer in metformin users [25, 26], while no effect has emerged from randomized clinical trials (RCTs) [26].”
BackgroundDickerman, B. A., García‐Albéniz, X., Logan, R. W., Denaxas, S., & Hernán, M. Á. (2023) · Epidemiology · doi:10.1097/ede.0000000000001626 · Cited by 42
“Nonsteroidal anti-inflammatory drug use 906 (9) 78,921 (8) 1,126 (9) 237,721 (8)”
Asiri, A., Qarni, A. A. A., & Bakillah, A. (2024) · Diagnostics · doi:10.3390/diagnostics14192132 · Cited by 44
“Although there are many antidiabetic drugs that are currently available, certain medications such as biguanides (metformin), thiazolidinediones (TZDs), and sulfonylureas (SUs) have shown anti-proliferative effects on various cancer cell types [186,187].”
Backgroundde Jong, R. G., Burden, A. M., de Kort, S., van Herk‐Sukel, M. P. P., Vissers, P. A. J., Janssen, P. K. C., Haak, H. R., Masclee, A., de Vries, F., & Janssen-Heijnen, M. L. G. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0277 · Cited by 37
Association between metabolic syndrome, diabetes mellitus and prostate cancer risk
Lawrence, Y. R., Morag, O., Benderly, M., Boyko, V., Novikov, I., Dicker, A. P., Goldbourt, U., Behar, S., Barchana, M., & Wolf, I. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.54 · Cited by 39
Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
Banno, K., Iida, M., Yanokura, M., Irie, H., Masuda, K., Kobayashi, Y., Tominaga, E., & Aoki, D. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/341362 · Cited by 43
“Several mechanisms of action for the antitumor effect of metformin have been proposed: activation of LKB1-AMP-activated protein kinase (LKB1-AMPK), which inhibits the mTOR pathway, with resultant induction of progesterone receptor (PR) expression and recovery of progesterone sensitivity [67, 68]; direct reduction of i…”
BackgroundMetformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro
UEHARA, T., Mitsuhashi, A., Tsuruoka, N., & Shozu, M. (2014) · Oncology Reports · doi:10.3892/or.2014.3611 · Cited by 40
Zhao, Y., Zeng, X., Tang, H., Ye, D., & Liu, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10119 · Cited by 36
“MET has attracted increased attention in recent years due to its possible anticancer activity; it inhibits several tumor types, including PCa (13-15).”
BackgroundColorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor Behind the Scene
Anwar, M. A., Kheir, W. A., Eid, S., Fares, J., Liu, X., Eid, A. H., & Eid, A. A. (2014) · Journal of Cancer · doi:10.7150/jca.9726 · Cited by 35
“Evidence from a panel of cancer cell lines (43, 67, 68), animal models (43, 68, 69) and epidemiological studies (70-73) suggests that metformin not only improves the life style and well-being, but lowers the rates of mortality in CRC (74) and PC (75).”
BackgroundResultThe exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC
Peduzzi, G., Archibugi, L., Farinella, R., Pisani, R. P. D. L., Vodičková, Ľ., Vodička, P., Kraja, B., Sáinz, J., Bars‐Cortina, D., Daniel, N., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.004 · Cited by 39
Chen, H., Cook, L. S., Tang, M.-T. C., Hill, D. A., Wiggins, C. L., & Li, C. I. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0291 · Cited by 37
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Zhang, Y., Zhou, F., Guan, J., Zhou, L., & Chen, B. (2023) · Biomolecules · doi:10.3390/biom13020250 · Cited by 41
Suissa, S., Dell’Aniello, S., & Renoux, C. (2023) · Epidemiology · doi:10.1097/ede.0000000000001628 · Cited by 37
Diabetes treatment in 2025: can scientific advances keep pace with prevalence?
Shomali, M. E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812465639 · Cited by 40
“More recently, metformin has been associated with reduced risk of cancer in observational studies, although this potential additional benefit needs to be confirmed in long-term randomized controlled trials [Noto et al. 2012].”
BackgroundColon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
Rokkas, T., & Portincasa, P. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.05.027 · Cited by 34
Metformin: update on mechanisms of action on liver diseases
Ruan, G., Wu, F., Shi, D., Sun, H., Wang, F., & Xu, C. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1327814 · Cited by 34
Medairos, R. A., Clark, J., Holoubek, S. A., Kubasiak, J., Pithadia, R., Hamid, F., Chmielewski, G. W., Warren, W. H., Basu, S., Borgia, J. A., et al. (2016) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.03.094 · Cited by 34
Seo, Y.-S., Kim, Y.-J., Kim, M., Suh, K., Kim, S. B., Han, C. J., Kim, Y. J., Jang, W. I., Kang, S. H., Tchoe, H. J., et al. (2016) · Medicine · doi:10.1097/md.0000000000003527 · Cited by 35
Barbieri, F., Verduci, I., Carlini, V., Zona, G., Pagano, A., Mazzanti, M., & Florio, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00135 · Cited by 35
Yousuf, Y., Datu, A., Barnes, B., Amini‐Nik, S., & Jeschke, M. G. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1480-x · Cited by 36
Smyth, L., Blunt, D. N., Gatov, E., Nagamuthu, C., Croxford, R., Mozessohn, L., & Cheung, M. C. (2020) · British Journal of Haematology · doi:10.1111/bjh.16635 · Cited by 34
“Studies assessing the impact of metformin on patients with lymphoma are limited and inconclusive.(12) One study with 24 individuals with diabetes treated with metformin reported statistically significant improvements in overall response and CR rates compared to a matched controlled cohort.”
BackgroundResultZurli, V., Montecchi, T., Heilig, R., Poschke, I. C., Volkmar, M., Wimmer, G., Boncompagni, G., Turacchio, G., D’Elios, M. M., Campoccia, G., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz1965 · Cited by 36
“In support of this, we observed that the treatment with the AMPK-activating anti-diabetic compound metformin, known for its anti-tumour activity (56), promotes granule polarization in CTLs (Figure S8).”
BackgroundUse of metformin and aspirin is associated with delayed cancer incidence
Sung, J. J. �., Ho, M.-W., Lam, A. S. M., Yau, S. T., & Tsoi, K. K. F. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101808 · Cited by 36
Singh, S. V., Chaube, B., Mayengbam, S. S., Singh, A., Malvi, P., Mohammad, N., Deb, A., & Bhat, M. K. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166011 · Cited by 39
Simó, R., Plana‐Ripoll, O., Puente, D., Morros, R., Mundet, X., Vilca, L. M., Hernández, C., Fuentes, I., Procupet, A., Tabernero, J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079968 · Cited by 37
“By contrast, metformin seemed to reduce the cancer in the same population of patients [19–25,40].”
BackgroundMATE2 Expression Is Associated With Cancer Cell Response to Metformin
Chowdhury, S., Yung, E., Pintilie, M., Muaddi, H., Chaib, S., Yeung, M., Fusciello, M., Sykes, J., Pitcher, B., Hagenkort, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165214 · Cited by 33
Huang, M.-Y., Chung, C., Chang, W., Lin, C., Chen, K., Hsieh, T., Chien, W., & Lin, H. (2017) · PubMed · Cited by 35
Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence
Flora, S. D., Ganchev, G., Iltcheva, M., Maestra, S. L., Micale, R. T., Steele, V. E., & Balansky, R. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.003 · Cited by 35
Sekino, N., Kano, M., Matsumoto, Y., Sakata, H., Akutsu, Y., Hanari, N., Murakami, K., Toyozumi, T., Takahashi, M., Otsuka, R., et al. (2018) · Cancer Science · doi:10.1111/cas.13523 · Cited by 34
“Metformin is an oral biguanide that has been used to treat type 2 DM worldwide for a long time, and the antitumor effects of metformin have been reported recently.(4) The main target of metformin is regarded as AMPK, which has various functions.”
BackgroundBecker, C., Jick, S. S., Meier, C. R., & Bodmer, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1719-6 · Cited by 33
“In recent years, use of the antidiabetic drug metformin has been linked to a decreased risk of some but not all cancer types [12–15].”
BackgroundTan, M. H., Alquraini, H., Mizokami‐Stout, K., & MacEachern, M. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.008 · Cited by 40
The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells
Gonnissen, A., Isebaert, S. F., McKee, C. M., Muschel, R. J., & Haustermans, K. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020399 · Cited by 33
Li, P., Zhang, C., Gao, P., Chen, X., Ma, B., Yu, D., Song, Y., & Wang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7370 · Cited by 35
“Furthermore, other meta-analyses (37-40) obtained similar results, suggesting an overall decrease in the risk of cancer by metformin.”
ResultJúnior, A. D. D. C., Pericole, F. V., & Carvalheira, J. B. C. (2018) · Clinics · doi:10.6061/clinics/2018/e412s · Cited by 35
“Since then, various studies in DM2 patients have shown that metformin use is associated with a reduced risk of several cancers (2,11,74-79), including prostate cancer (80,81), lung cancer (45,82,83), head and neck cancer (HNC) (84,85), breast cancer (86-88), pancreatic cancer (89), CRC (90-92), endometrial cancer (93)…”
BackgroundTanaka, K., Tsuji, I., Tamakoshi, A., Matsuo, K., Wakai, K., NAGATA, C., Mizoue, T., Inoue, M., Tsugane, S., Sasazuki, S., et al. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu108 · Cited by 33
Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer
Park, S., Willingham, M. C., Qi, J., & Cheng, S.-Y. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0071 · Cited by 32
Lack of Effect of Metformin on Mammary Carcinogenesis in Nondiabetic Rat and Mouse Models
Thompson, M. D., Grubbs, C. J., Bode, A. M., Reid, J. M., McGovern, R. M., Bernard, P. S., Stijleman, I. J., Green, J. E., Bennett, C. N., Juliana, M. M., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0181-t · Cited by 32
“Recently, there has been great interest in the use of metformin as a potential chemopreventive/therapeutic agent based on epidemiologic studies showing a lower incidence of cancer and lower toxicity in diabetics taking this drug compared to those taking sulfonylurea or insulin (3,4).”
Case–control analysis on metformin and cancer of the esophagus
Becker, C., Meier, C. R., Jick, S. S., & Bodmer, M. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0253-6 · Cited by 32
“Anti-diabetic drugs have also been shown to affect cancer risk, and long-term metformin use has been associated with reduced risks for some cancer types and for cancer overall [18–21].”
BackgroundMetformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients
Dhillon, S. S., Groman, A. E., Meagher, A. K., Demmy, T. L., Warren, G. W., & Yendamuri, S. (2014) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000275 · Cited by 32
“Recent studies suggest that diabetes mellitus (DM) and metformin may affect cancer incidence and mortality [10,11].”
BackgroundObara, A., Fujita, Y., Abulizi, A., Fukushima, T., Oguri, Y., Ogura, M., Harashima, S., Hosokawa, M., & Inagaki, N. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.03.148 · Cited by 32
“Epidemiologic evidence suggests that metformin reduces the risk of cancers in patients with diabetes [5, 6].”
BackgroundJoo, M. K., Park, J., & Chun, H. J. (2017) · Digestive Diseases · doi:10.1159/000480149 · Cited by 31
Antidiabetic drugs and risk of cancer
Tokajuk, A., Krzyżanowska-Grycel, E., Tokajuk, A., Grycel, S., Sadowska, A., & Car, H. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.05.005 · Cited by 31
Diabetes mellitus, metformin and head and neck cancer
Figueiredo, R. A. D. O., Weiderpass, E., Tajara, E. H., Ström, P., Carvalho, A. L., de Carvalho, M. B., Kanda, J. L., Moysés, R. A., & Wünsch‐Filho, V. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.08.006 · Cited by 31
“In one study, a group of rats with chronic ethanol consumption showed a reduction in AMPK enzyme, but the group with ethanol consumption and treated with metformin showed improvement in hepatic injury through activation of AMPK.”
BackgroundInfluentialLeonel, C., Borin, T. F., Ferreira, L. D. C., Moschetta, M. G., Bajgelman, M. C., Viloria‐Petit, A., & Zuccari, D. A. P. D. C. (2017) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-016-9370-7 · Cited by 30
“Following epidemiological findings linking the use of metforming to reduced incidence of certain cancers, particularly of the breast [20],”
BackgroundInfluentialDiabetes in the practice of otolaryngology
Atsmoni, S. C., Brener, A., & Roth, Y. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.006 · Cited by 33
Metformin ameliorates acetaminophen-induced sub-acute toxicity via antioxidant property
Tripathi, S. S., Singh, S., Garg, G., Kumar, R., Verma, A. K., Singh, A. K., Bissoyi, A., & Rizvi, S. I. (2019) · Drug and Chemical Toxicology · doi:10.1080/01480545.2019.1658769 · Cited by 34
“In several clinical studies, it has been reported that metformin is significantly effective in the protection of liver cells in nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) as well as hepato-carcinoma (Noto et al. 2012).”
BackgroundChuang, M.-C., Yang, Y.-H., Tsai, Y.-H., Hsieh, M.-J., Lin, Y.-C., Lin, C.-K., Chen, P.-C., & Yang, T.-M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191129 · Cited by 29
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer
Nunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207768 · Cited by 34
Mdkhana, B., Zaher, D. M., Abdin, S. M., & Omar, H. A. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153470 · Cited by 31
Metformin in lung cancer: rationale for a combination therapy
Morgillo, F., Sasso, F. C., Corte, C. M. D., Festino, L., Manzo, A., Martinelli, E., Troiani, T., Capuano, A., & Ciardiello, F. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.828691 · Cited by 30
“[19] with the intent to estimate the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes.”
BackgroundSystematic review and meta-analysis of rectal washout on risk of local recurrence for cancer
Zhou, C., Ren, Y. T., Li, J., Xiao, L., He, J., & Liu, P. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.01.030 · Cited by 31
“Consequently , we are reluctant to admit that surgeons will never be sure whether this time honored practice is justified, until the results of a randomized, controlled clinical trial comparing intra-operative washout types and irrigation volumes are available [50], though the cost and time to perform a washout is so…”
BackgroundWu, Y., Liu, H., Shi, X., & Song, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099577 · Cited by 29
“In our study, we included more studies and also found that metformin was associated with a 15% decreased risk of lung cancer in observational studies, This protective potential of metformin use agrees with previous meta-analysis [20].”
BackgroundResultInfluentialAlbini, A., Bassani, B., Baci, D., Dallaglio, K., Gallazzi, M., Corradino, P., Bruno, A., & Noonan, D. M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170920144130 · Cited by 33
Oxidative and Glycolytic Metabolism: Their Reciprocal Regulation and Dysregulation in Cancer
Cordani, M., Rumio, C., Bontempi, G., Strippoli, R., & Marcucci, F. (2025) · Cells · doi:10.3390/cells14151177 · Cited by 32
“An antitumor activity of metformin has been suggested by the observation that its use was associated with a lower risk of cancer incidence in diabetic patients [141].”
Chen, B., Ye, P., Chen, Y., Liu, T., Cha, J., Yan, X., & Yang, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01657 · Cited by 33
“Metformin, an antidiabetic drug, has recently been reported to reduce tumor risk in some cancers associated with diabetes, including breast cancer (130, 131).”
BackgroundMetformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis
Grossmann, M. E., Yang, D.-Q., Guo, Z., Potter, D. A., & Cleary, M. P. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0032-z · Cited by 29
Changes in sedentary behaviours across the retirement transition: a systematic review.
MURPHY, M. H. (2015) · PubMed · doi:10.1093/ageing/afv142 · Cited by 1
“We therefore opted to use the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist [17] as it comprehensively examines numerous aspects of studies’ designs and reporting and has been used for risk of bias scoring in previous systematic reviews [18, 19].”
MethodDiabetology and oncology meet in a network model: union is strength
Gallo, M., Gentile, L., Arvat, E., Bertetto, O., & Clemente, G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0839-z · Cited by 29
“Conversely, metformin has been repeatedly associated with a lower risk of cancer morbidity and mortality [17, 18] and suggested to act as an anti-tumoral agent in non-diabetic individuals.”
BackgroundTranslational geroscience: From invertebrate models to companion animal and human interventions
Lee, M. B., & Kaeberlein, M. R. (2018) · Translational Medicine of Aging · doi:10.1016/j.tma.2018.08.002 · Cited by 36
Noh, Y., Jeon, S., & Shin, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.31870 · Cited by 29
Yamana, H., Kato, K., Kobara, H., Fujihara, S., Fujita, K., Namima, D., Fujita, N., Kobayashi, K., Kamada, H., Morishita, A., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13933 · Cited by 30
Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview
Ashraf-Uz-Zaman, M., Bhalerao, A., Mikelis, C. M., Cucullo, L., & German, N. (2020) · Cancers · doi:10.3390/cancers12051265 · Cited by 28
Rewiring cancer metabolism: oncogenic signaling pathways and targeted therapeutics
Lyu, S., Gildor, N., Zhang, Q. H., & Liao, C. (2025) · Science China Life Sciences · doi:10.1007/s11427-025-2979-3 · Cited by 30
“Metformin, which inhibits complex I of the ETC as previously mentioned, has been shown to lower ROS production, which was then linked with a lower risk of cancer incidence and mortality (Noto et al., 2012).”
Chappell, W. H., Abrams, S. L., Franklin, R. A., LaHair, M. M., Montalto, G., Cervello, M., Martelli, A. M., Nicoletti, F., Candido, S., Libra, M., et al. (2012) · Cell Cycle · doi:10.4161/cc.22786 · Cited by 27
Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention
Pulito, C., Sanli, T., Rana, P., Muti, P. C., Blandino, G., & Strano, S. (2013) · Metabolites · doi:10.3390/metabo3041051 · Cited by 33
“Five recent meta-analysis have pooled data from studies which look at the potential use of metformin in cancer prevention in diabetic patients [126–130].”
MethodIzzotti, A., Balansky, R. M., D’Agostini, F., Longobardi, M., Cartiglia, C., Micale, R. T., Maestra, S. L., Camoirano, A., Ganchev, G., Iltcheva, M., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.234 · Cited by 29
“[9], a significant decrease in both incidence and mortality for all cancers was reported among metformin users, with significant decreases of incidence for colorectal cancer, hepatocellular cancer, and lung cancer.”
BackgroundThe prognostic role of metformin in patients with endometrial cancer: a retrospective study
Seebacher, V., Bergmeister, B., Grimm, C., Koelbl, H., Reinthaller, A., & Polterauer, S. (2016) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.06.013 · Cited by 27
Higher risk of mortality from lung cancer in Taiwanese people with diabetes
Tseng, C. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.10.019 · Cited by 28
“[35] Noto H, Goto A, Tsujimoto T, Noda M.”
BackgroundMetformin and the risk of head and neck cancer: a case–control analysis
Becker, C., Jick, S. S., Meier, C. R., & Bodmer, M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12351 · Cited by 27
“breast cancer, cancer of the pancreas or liver) and for cancer overall but results remain controversial [18,19].”
BackgroundKi, Y.-J., Kim, H. J., Kim, M.-S., Park, C. M., Ko, M. J., Seo, Y. S., Moon, S. M., & Choi, J. A. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.128 · Cited by 27
Metformin: (future) best friend of the radiation oncologist?
Chevalier, B., Pasquier, D., Lartigau, E. F., Chargari, C., Schernberg, A., Jannin, A., Mirabel, X., Vantyghem, M., & Escande, A. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.06.030 · Cited by 28
Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
Vitali, E., Boemi, I., Tarantola, G., Piccini, S., Zerbi, A., Veronesi, G., Baldelli, R., Mazziotti, G., Smiroldo, V., Lavezzi, E., et al. (2020) · Cancers · doi:10.3390/cancers12082143 · Cited by 29
“1-dimethylbiguanide hydrochloride), a widely used antidiabetic drug, was associated with significantly lower risks of cancer incidence and mortality [15].”
BackgroundThe Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
Welters, M. J. P., Santegoets, S. J. A. M., & van der Burg, S. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.545385 · Cited by 29
Targeting the Metabolic Paradigms in Cancer and Diabetes
Bosso, M., Haddad, D., Madhoun, A. S. A., & Al‐Mulla, F. (2024) · Biomedicines · doi:10.3390/biomedicines12010211 · Cited by 30
“For instance, Noto et al. (2012) conducted a systematic meta-analysis on 6 studies (4 cohort studies, 2 RCTs), with data from a total of 210,829 diabetic patients [3].”
BackgroundOhno, T., Shimizu, M., Shirakami, Y., Baba, A., Kochi, T., Kubota, M., Tsurumi, H., Tanaka, T., & Moriwaki, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124081 · Cited by 28
miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7
Zhao, W., Zhang, X., Liu, J., Sun, B., Tang, H., & Zhang, H. (2016) · Oncology Reports · doi:10.3892/or.2016.5199 · Cited by 29
Assatse, Y. T., Ejuh, G. W., Tchoffo, F., & Ndjaka, J. M. B. (2019) · Chinese Journal of Physics · doi:10.1016/j.cjph.2019.01.014 · Cited by 27
Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?
Voorde, L. V. D., Janssen, L., Larue, R. T. H. M., Houben, R. M. A., Buijsen, J., Sosef, M. N., Vanneste, B. G. L., Schraepen, M.-C., Berbée, M., & Lambin, P. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.05.012 · Cited by 30
Assi, A. A., Posty, S., Lamarche, F., Chebel, A., Guitton, J., Cottet‐Rousselle, C., Prudent, R., Lafanéchère, L., Giraud, S., Dallemagne, P., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06668-9 · Cited by 28
“Indeed, epidemiological studies have shown that its widespread use reduces cancer incidence in diabetic patients [21, 22], although the magnitude of this effect has been debated [23].”
Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells
Pabona, J. M. P., Burnett, A., Brown, D. M., Quick, C. M., Simmen, F. A., Montales, M. T. E., Liu, S. J., Rose, T., Alhallak, I., Siegel, E. R., et al. (2020) · Reproductive Sciences · doi:10.1007/s43032-019-00019-2 · Cited by 25
Metformin usage and the risk of colorectal cancer: a national cohort study
Lee, J., Choi, E.-A., Kim, Y.-S., Kim, Y., You, H., Han, Y.-E., Kim, H.-S., Bae, Y., Kim, J., & Kang, H. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03765-x · Cited by 26
Chemoprevention of Lung Cancer: Prospects and Disappointments in Human Clinical Trials
Greenberg, A. K., Tsay, J.-C. J., Tchou-Wong, K.-M., Jorgensen, A., & Rom, W. N. (2013) · Cancers · doi:10.3390/cancers5010131 · Cited by 25
“As mentioned above, observational studies have found a decreased incidence of lung cancer in diabetics treated with metformin compared with other agents [105,106], although not all studies confirm this observation [107,108].”
ResultShi, R., Lin, J., Gong, Y., Yan, T., Shi, F., Yang, X., Liu, X., & Naren, D. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000266 · Cited by 27
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 29
“…lines of research in this area pertains to evidence of its protective effects against cancer, with early meta-analyses reporting risk reductions in both cancer incidence and mortality associated with metformin of approximately 30–40 % (Decensi et al., 2010; Zhang et al., 2013; Noto et al., 2012).”
Targeting the pH Paradigm at the Bedside: A Practical Approach
Koltai, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239221 · Cited by 26
Do endometrial cancer patients benefit from metformin intake?
Lemańska, A., Zaborowski, M. P., Spaczyński, M., & Nowak‐Markwitz, E. (2015) · Ginekologia Polska · doi:10.17772/gp/2397 · Cited by 27
Prevention and Intervention Trials for Colorectal Cancer
Komiya, M., Fujii, G., Takahashi, M., Iigo, M., & Mutoh, M. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt053 · Cited by 24
Effects of metformin on retinoblastoma growth in vitro and in vivo
Brodowska, K., Theodoropoulou, S., zu Hörste, M. M., Paschalis, E. I., Takeuchi, K., SCOTT, G., Ramsey, D. J., Kiernan, E. A., Hoang, M. V., Cichy, J., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2650 · Cited by 24
“Some retrospective epidemiologic studies have revealed a decrease in the incidence of certain cancers in patients treated with metformin (48-50).”
BackgroundThe Antitumor Effects of Metformin on Gastric Cancer In Vitro and on Peritoneal Metastasis
Sekino, N., Kano, M., Matsumoto, Y., Sakata, H., Murakami, K., Toyozumi, T., Otsuka, R., Yokoyama, M., Shiraishi, T., Okada, K., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12982 · Cited by 25
Spierings, L. E. A. M. M., Lagarde, S. M., van Oijen, M. G. H., Gisbertz, S. S., Wilmink, J. W., Hulshof, M. C. C. M., Meijer, S. L., Anderegg, M. C. J., Henegouwen, M. I. V. B., & van Laarhoven, H. W. M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4850-3 · Cited by 27
Cancer chemoprevention is not a failure
Adhami, V. M., Bailey, H. H., & Mukhtar, H. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu141 · Cited by 24
“A systematic review and meta-analyses of worldwide reports demonstrated that metformin is associated with a substantially lower risk of all-cancer mortality and incidence, compared with other treatments for diabetes (21).”
ResultKalainayakan, S. P., Ghosh, P., Dey, S., FitzGerald, K. E., Sohoni, S. S., Konduri, P. C., Garrossian, M., Liu, L., & Li, Z. (2019) · Scientific Reports · doi:10.1038/s41598-018-38345-1 · Cited by 29
Chao, R., Nishida, M., Yamashita, N., Tokumasu, M., Zhao, W., Kudo, I., & Udono, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864225 · Cited by 25
Moradinazar, M., Najafi, F., Rajati, F., Sarokhani, D., & Bavandpour, M. (2023) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_62_21 · Cited by 29
“[18,26] Previous studies have shown that metformin at lower doses can block HER2 activity.”
BackgroundInfluentialSteenkamp, D., McDonnell, M. E., & Meibom, S. K. (2014) · Endocrine Practice · doi:10.4158/ep14127.ra · Cited by 24
Metformin and Breast Cancer Stage at Diagnosis: A Population-Based Study
Lega, I. C., Fung, K., Austin, P. C., & Lipscombe, L. L. (2017) · Current Oncology · doi:10.3747/co.24.3380 · Cited by 25
Metformin and Colorectal Cancer – A Systematic Review.
Kobiela, J., Dobrzycka, M., Jędrusik, P., Kobiela, P., Spychalski, P., Śledziński, Z., & Zdrojewski, T. R. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0621-8830 · Cited by 24
Metadata
- Authors
- Noto, H., Goto, A., Tsujimoto, T., & Noda, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- Corresponding author
- Noto, Hiroshi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-20
- Volume
- 7
- Issue
- 3
- Pages
- e33411
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3308971
- OpenAlex
- W2040608814
- Cited by
- 566
- References
- 106
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 20 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 41 · 2019: 38 · 2018: 28 · 2017: 50 · 2016: 60 · 2015: 57 · 2014: 60 · 2013: 65 · 2012: 25
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, diabetes mellitus, cancer risk, cancer mortality, cancer incidence, colorectal cancer, hepatocellular carcinoma, lung cancer, chemoprevention
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.